本帖最后由 老马 于 2013-3-13 13:43 编辑
' c4 P6 ], d0 c& D% I1 g2 H \0 ^4 \/ w
健择（吉西他滨）+顺铂+阿瓦斯汀
; ~0 `4 G$ E. o+ x1 L- L Gemzar +Cisplatin + Avastin
' Q: {6 X# m+ V. {; E1 b4 w' H3 Ghttp://annonc.oxfordjournals.org/content/21/9/1804.full
+ h9 T/ c2 |' f3 K$ u% R& eOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) $ m+ V9 a6 o- _! d( v* M
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 5 l5 v" u4 m. _$ A& j3 O& M
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& J. D% G1 }8 ]7 d
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 253)
3 a8 H* r5 ?8 o华为网盘附件：
* s+ o4 _4 \( `【华为网盘】ava.JPG& o. _8 @; i$ r" V
|
显身卡
